Ann Neurol
- CHOMYK A, Kucinski R, Kim J, Christie E, et al
Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic
Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
BMC Neurol
- GHAZANFARI HASHEMI M, Talebi V, Abbasi Kasbi N, Abbasi M, et al
T1 hypointense brain lesions in NMOSD and its relevance with disability: a single
institution cross-sectional study.
BMC Neurol. 2024;24:62.
Can J Neurol Sci
- NOBILE S, Beauchemin P
Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple
Sclerosis Cohort.
Can J Neurol Sci. 2024 Feb 12:1-21. doi: 10.1017/cjn.2024.
J Neuroimmunol
- LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
Effects of treadmill training on myelin proteomic markers and cerebellum
morphology in a rat model of cuprizone-induced toxic demyelination.
J Neuroimmunol. 2024;387:578286.
- TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed
meninges in a chronic model of central nervous system autoimmunity.
J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
J Neurol
- HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
Prodromal multiple sclerosis: considerations and future utility.
J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
J Neurol Sci
- BALCOM EF, Smyth P, Kate M, Vu K, et al
Disease-modifying therapy use and health resource utilisation associated with
multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
J Neurol Sci. 2024;458:122913.
Mult Scler
- LANGDON D
Neuropsychological assessment in MS is outdated and in need for innovation: NO.
Mult Scler. 2024;30:152-153.
- KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
Autologous hematopoietic stem cell transplantation for multiple sclerosis:
Long-term follow-up data from Norway.
Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
- PATEL S, Rafferty S, Aquino L, Chadha S, et al
VISIBL-MS: A bilingual educational framework to increase awareness of early
multiple sclerosis.
Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
- COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple
Sclerosis Society.
Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
- HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
A custom-built step exergame training programme to prevent falls in people with
multiple sclerosis: A multicentre randomised controlled trial.
Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
N Engl J Med
- HAUSER SL
Silencing Immune Dialogue in Multiple Sclerosis.
N Engl J Med. 2024;390:662-663.
- VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
N Engl J Med. 2024;390:589-600.
Neurology
- SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial
Populations.
Neurology. 2024;102:e209135.
- CHARD DT
Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New
Perspective on an Old Foe.
Neurology. 2024;102:e209246.
- ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple
Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
Neurology. 2024;102:e208058.
PLoS One
- DADVAR A, Jameie M, Azizmohammad Looha M, Parsaei M, et al
Potential efficacy of caffeine ingestion on balance and mobility in patients with
multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial.
PLoS One. 2024;19:e0297235.
Proc Natl Acad Sci U S A
- ADAMS C, Manouchehrinia A, Quach HL, Quach DL, et al
Evidence supports a causal association between allele-specific vitamin D receptor
binding and multiple sclerosis among Europeans.
Proc Natl Acad Sci U S A. 2024;121:e2302259121.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016